Balyasny Asset Management L.P. Purchases Shares of 529,653 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Balyasny Asset Management L.P. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 529,653 shares of the biotechnology company’s stock, valued at approximately $3,983,000. Balyasny Asset Management L.P. owned 0.26% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the period. Raymond James Financial Inc. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $80,000. Finally, Syon Capital LLC purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $99,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BCRX. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 target price on the stock. Barclays raised their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:BCRX opened at $9.98 on Friday. The company has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.34 and a fifty-two week high of $11.11. The firm has a 50-day simple moving average of $7.87 and a 200 day simple moving average of $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter last year, the firm earned $0.28 EPS. The company’s revenue for the quarter was up 40.8% on a year-over-year basis. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.